The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Quarterly Activities/Appendix 4C Cash Flow Report
April 30, 2024
BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”), a plant-based biotechnology company, today released its Appendix 4C and Quarterly Activities Report for the period ended 31 March 2024.
Corporate activities
BP8 ended the quarter with cash of approximately $0.257 million ($0.367 million at 31 December 2023).
On 23 April 2024, the Company issued a notice of general meeting to be convened on 24 April 2024 (Notice of Meeting) at which the Company will seek shareholder approval pursuant to ASX Listing Rule 7.1 to undertake a share placement to sophisticated and professional investors. The share placement authority is for the Company to raise up to $1,000,000. Further details regarding the proposed share placement can be found in the Notice of Meeting.
Total aggregate cash payments of $56,000 were made during the quarter to related parties and their associates as remuneration. Details of these payments are included in items 6 of the Appendix 4C.
Renewal of China Tobacco Sales and Distribution Agreements
Following the Company’s acquisition of Foshan Gedishi Biotechnology Co Ltd (Foshan) in the December quarter, the Company announced on 6 February 2024 the renewal of the two (2) sales and distribution agreements from 2023 between the Company’s now wholly owned subsidiary Foshan and two (2) wholly owned subsidiaries of China Tobacco based in Guangzhou City in the Province of Guangdong (2023 Agreements). The two wholly owned subsidiaries are Guangzhou Gold Leaves Franchise Co Ltd (Golden Leaves) and Guangzhou City Twenty Sticks Commercial Franchise Co Ltd (Twenty Sticks).
The principal terms of the 2024 Agreements include:
- commencement date 1 January 2024;
- term 12 months;
- products to be supplied:
- pure bird’s nest 50g box;
- pure bird’s nest 100g box; and
- bird’s nest drink - each box contains 3 bottles with 1.5g bird nest content; and
- products to be sold in China Tobacco outlets in the Guangzhou Province of China.
Initial sales results
Foshan commenced its sales of bird’s nest products as the Company’s wholly owned subsidiary in early January 2024 in the lead up to Chinese (Lunar) New Year (which commenced in early February 2024).
Click here for the full ASX Release
This article includes content from BPH Global Ltd, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
BP8:AU
Sign up to get your FREE
BPH Global Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
01 December 2021
BPH Global
Stemcell United Ltd is a marine and agricultural biotechnology industry. Its only operating segment being sourcing, producing, marketing, and selling traditional medicines. The company's geographical segment includes Australia; Singapore; Malaysia and Greater China. The company's product includes Cannabis sativa; Dendrobium Officinale and Daemonorops Draco Blume.
01 July
Investor Webinar – 3pm AEST Tuesday 2 July
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.
When: 3pm AEST, Tuesday 2 July 2024
Register at: https://us02web.zoom.us/webinar/register/WN_wcKESuixTf2e5TRIwVAW_Q
Upon registering attendees will receive an email containing information about joining the webinar. A recording will be available at the above link soon after the conclusion of the live session, with the replay to also be made available via Radiopharm’s website and social media channels.
Questions can be sent in advance of the webinar to matt@nwrcommunications.com.au.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. Learn more at Radiopharmtheranostics.com.
Click here for the full ASX Release
This article includes content from Radiopharm Theranostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
25 June
Oncology Stocks: 8 Biggest NASDAQ Companies in 2024
The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.
Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.
At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.
As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.
This list of the biggest oncology stocks on the NASDAQ was generated using TradingViews's stock screener. The companies are listed in order of market cap, and all figures below were current as of June 19, 2024.
1. AstraZeneca (NASDAQ:AZN)
Market cap: US$244.56 billion; current share price: US$78.42
First on this list of the top NASDAQ oncology companies by market cap is multinational pharma and biotech firm AstraZeneca, which also specializes in several other therapeutic areas, including cardiovascular, respiratory, central nervous system and pain control. The company is aiming to strengthen its position in the oncology market by more than doubling its cancer drug offerings by 2030.
AstraZeneca has several partnerships with other pharma companies, including Merck (NYSE:MRK). The pair brought PARP-inhibitor LYNPARZA to market as a monotherapy and in combination to address multiple cancer types, including in certain breast, prostate, pancreatic and ovarian tumors. The drug’s revenues for these indications are expected to reach US$4 billion by 2027, representing more than 68 percent of the projected global PARP inhibitors market for that year.
2. Amgen (NASDAQ:AMGN)
Market cap: US$164.14 billion; current share price: US$305.99
One of the world's leading independent biotechnology companies, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting oncological diseases, including a range of solid tumors and hematologic malignancies.
Amgen is advancing a robust pipeline with several mid- to late-stage candidates, including drug candidates targeting leukemia, colorectal cancer and solid tumors. Amgen's oncology portfolio includes first-in-class Bispecific T-cell Engager (BiTE) therapy Blincyto, which in June received US Food and Drug Administration (FDA) approval for the treatment of adult and pediatric patients with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia in the consolidation phase.
This is the second BiTE therapy from Amgen to gain FDA approval. The company's Imdelltra (tarlatamab) got the nod in May for treating adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
3. Sanofi (NASDAQ:SNY)
Market cap: US$119.61 billion; current share price: US$47.22
Based in France, Sanofi is developing new technologies based on molecular oncology, immuno-oncology and genomic medicine platforms targeting some of the most difficult-to-treat cancers. The company's oncology strategy encompasses four disease areas: blood cancers, including multiple myeloma; skin cancers; lung cancers; and breast cancer and other hormone-positive cancers.
Sanofi's oncology pipeline includes 13 drug candidates in clinical development, with a focus on solid tumors, leukemia, and myeloma. In June, the company shared positive data from its Phase 3 IMROZ regimen study of Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd. The results demonstrated a significant reduction in the risk of disease progression or death by 40 percent when compared to VRd followed by Rd alone.
4. Regeneron Pharmaceuticals (NASDAQ:REGN)
Market cap: US$114.48 billion; current share price: US$1,039.11
Biotech leader Regeneron Pharmaceuticals develops and commercializes medicines targeting cancer, pain and a wide variety of diseases, including inflammatory, cardiovascular, metabolic, hematologic and rare diseases.
The company’s drug candidate portfolio includes 18 clinical-stage programs targeting various cancers, including solid tumors, prostate cancer, cervical cancer and metastatic melanoma. Its 12 FDA approved drugs include Libtayo (cemiplimab-rwlc) for cutaneous squamous cell carcinoma, basal cell carcinoma and non-small cell lung cancer.
In an effort to expand its cell therapy research, Regeneron acquired biotech 2Seventy Bio’s (NASDAQ:TSVT) cancer drug pipeline earlier this year.
“Our expertise in antibody technologies and emerging genetics capabilities, combined with 2seventy’s cell therapy platforms, presents a significant opportunity to address cancer and other serious diseases in new and impactful ways,” said George Yancopoulos, Regeneron’s chief scientific officer, in a statement.
5. Gilead Sciences (NASDAQ:GILD)
Market cap: US$78.68 billion; current share price: US$63.15
Global biopharmaceutical company Gilead Sciences is in the business of developing breakthrough medicines to prevent and treat serious conditions such as HIV, viral hepatitis and cancer. Last year, the company built up its early oncology pipeline with the acquisition of biotech firm XinThera and its portfolio of small molecule inhibitors targeting PARP1.
One of Gilead's biggest successes is Yescarta, a CAR-T cell therapy for blood cancer and the first such therapy for certain types of non-Hodgkin's lymphoma. Earlier this year, Reuters reported that improvements in its manufacturing process will allow the company "to quadruple production of its cell therapy cancer treatments by 2026."
6. Moderna (NASDAQ:MRNA)
Market cap: US$51.05 billion; current share price: US$133.27
Moderna is a leader in applied mRNA science with a diverse clinical portfolio of vaccines and therapeutics. Its mRNA platform harnesses the body's immune system to identify and kill cancer cells, including individualized mRNA-based personalized cancer vaccines.
In June, Moderna and Merck released positive three-year data from a clinical study evaluating the use of an experimental vaccine in combination with Merck's FDA-approved Keytruda in the treatment of melanoma, the most deadly form of skin cancer. The data showed improved survival rates and long-lasting efficacy.
7. BioNTech (NASDAQ:BNTX)
Market cap: US$20.51 billion; current share price: US$86.27
Biopharma BioNTech is advancing immunotherapies for serious diseases, including various forms of cancer. The company’s oncology portfolio includes mRNA-based therapies, CAR-T cell therapies and targeted cancer antibodies.
BioNTech has a collaboration deal with China-based biotech company Duality Biologics to develop, manufacture and license multiple antibody-drug conjugate candidates targeting solid tumors. Early this year, the FDA granted fast track designation for one of them, the candidate BNT325/DB-1305 for the treatment of platinum-resistant ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer in patients who have previously received one to three systemic treatment regimens.
However, in mid-June the FDA placed a partial hold on the Phase 1 trial for the candidate after BioNTech disclosed the deaths of three patients due to “treatment-related adverse effects.” The partial hold prevents the enrollment of any new US patients in the study.
“The fact that patients already enrolled in the Phase I BNT326/YL202 study will continue to receive the drug suggested that the FDA’s concerns were manageable,” commented John Newman, PhD, a senior biotechnology analyst with Canaccord Genuity.
8. Illumina (NASDAQ:ILMN)
Market cap: US$17.22 billion; current share price: US$108.10
Illumina develops, manufactures and markets life science tools and integrated systems that enable the implementation of genomic solutions for the healthcare sector with a focus on oncology testing, genetic disease testing, reproductive health and research. The company is expanding its next-generation sequencing oncology portfolio to help clinical cancer researchers estimate tumor mutational burden, identify neoantigens and study innovative therapies to boost the immune response.
In January, Illumina announced an expansion of its collaboration with Janssen Research & Development for the development of the latter's novel molecular residual disease assay. The assay is based on using whole-genome sequencing for multi-cancer research for the detection of circulating tumor DNA. The purpose is to better understand how oncological diseases can persist reoccur following treatment, and it will look at samples "from patients previously diagnosed with cancer across multiple solid tumor indications," according to the release.
This is an updated version of an article first published by the Investing News Network in 2018.
Don’t forget to follow us @INN_LifeScience for real-time updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Keep reading...Show less
25 June
Radiopharm Theranostics Limited (ASX: RAD) – Reinstatement to Quotation
Description
The suspension of trading in the securities of Radiopharm Theranostics Limited (‘RAD’) will be lifted immediately following the release by RAD of an announcement regarding its capital raising.
ASX Compliance
Click here for the full ASX Release
This article includes content from Radiopharm Theranostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
25 June
Radiopharm Theranostics Completes A$70 Million Placement
Radiopharm Theranostics Limited (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, has received firm commitments to raise approximately A$70.0 million (before costs) by way of a placement (the Placement) comprised of international and Australian institutional and industry investors, including Lantheus Holdings (“Lantheus”) and specialist US healthcare investors.
- Radiopharmaceutical industry leader, Lantheus Holdings, Inc., has agreed to make an initial strategic equity investment of A$7.5m at A$0.05 per share, which represents a 47% premium to last closing price of A$0.034 on 19 June 2024
- Two Tranche Placement to raise an additional A$62.5m, taking total amount raised under the placement to A$70.0m
- Offer price for shares issued under the balance of the placement of A$0.04 represents an 18% premium to the last closing price
- Participation from leading international institutional investors including US specialist healthcare investors
- Net proceeds are expected to fully fund the current clinical programs until the end of 2026
- Executive Chair, Paul Hopper, to participate in the placement with A$3.0 million investment, subject to shareholder approval
- Option for Lantheus to invest a further A$7.5m within 6 months on the same terms
- Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement
As part of the Placement, as announced on 20 June 2024 and subject to shareholder approval, Lantheus has subscribed for:
- a) A$7.5 million (US$4.99 million) at A$0.05 (US$0.033) per share;
- b) unlisted options with a six-month term after the date the subscription shares are issued to invest up to an additional A$7.5 million (US$5 million) at A$0.05 (US$0.033) per share; and
- c) one option for every four shares subscribed for (inclusive of any shares further subscribed for in the next six months), exercisable at A$0.06 per option expiring in August 2026, (together, “Lantheus Interests”).
Riccardo Canevari, Radiopharm’s Chief Executive Officer & Managing Director, said “We are delighted to complete this significant capital raise which will allow us to accelerate the development of our portfolio, as well as provide an expected cash runway to the end of 2026. To have attracted investment from Lantheus, one of the radiopharmaceutical industry’s leading companies, is a solid endorsement of RAD’s potential. We look forward to working closely with Lantheus in the coming years.”
As announced on 20 June 2024, and separate to the Placement, under a separate transfer and development agreement, RAD has agreed to assign and sub-license two of its preclinical assets to Lantheus for A$3.0 million (US$2.0 million). Assets covered under the agreement are a TROP2 targeting nanobody and a LRRC15 targeting mAb.
“We are pleased to make a strategic investment in RAD and partner with them to further expand our innovative pipeline,” said Brian Markison, Chief Executive Officer of Lantheus. “Radiopharmaceutical theranostics are changing the way cancer is diagnosed and treated, yet we still have more work to do and are inspired to further advance this field with these two preclinical oncology assets.”
An Extraordinary General Meeting (“EGM”) to approve the Lantheus Interests, second tranche component of the Placement (as described further below), and all options offered under the capital raising is anticipated to be held in early August 2024.
Bell Potter Securities Limited acted as lead manager to the capital raising and B. Riley Securities Inc acted as US placement agent. B. Riley Securities is acting as financial advisor to the Company on the Lantheus transactions.
Click here for the full ASX Release
This article includes content from Radiopharm Theranostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
20 June
Radiopharm Receives Strategic Investment for up to A$18 million
Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.
- Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm
- Offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024
- Option for Lantheus to invest a further A$7.5m within 6 months on the same terms
- Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement
The net proceeds of Lantheus’ investment will be used by the Company for drug manufacturing, clinical trials and general working capital.
Subject to shareholder approval for the purposes of ASX Listing Rule 7.1, under a subscription agreement entered into with Radiopharm (Subscription Agreement), Lantheus has subscribed for up to:
a) A$7.5 million (US$4.99 million) at A$0.05 (US$0.033) per share;
b) unlisted options with a six-month term after the date the subscription shares are issued to invest up to an additional A$7.5 million (US$5 million) at A$0.05 (US$0.033) per share; and
c) one option for every four shares subscribed for (inclusive of any shares further subscribed for in the next six months), exercisable at A$0.06 per option expiring in August 2026.
Under a separate transfer and development agreement, Radiopharm has assigned and sub- licensed two of its preclinical assets to Lantheus for A$3.0 million (US$2.0 million). Assets covered under the agreement are a TROP2 targeting nanobody and a LRRC15 targeting mAb.
B. Riley Securities is acting as financial advisor to the Company on the Lantheus transactions.
Click here for the full ASX Release
This article includes content from Radiopharm Theranostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
20 June
Radiopharm Theranostics Limited (ASX: RAD) – Trading Halt
Description
The securities of Radiopharm Theranostics Limited (‘RAD’) will be placed in trading halt at the request of RAD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 June 2024 or when the announcement is released to the market.
ASX Compliance
Click here for the full ASX Release
This article includes content from Radiopharm Theranostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
Latest News
Sign up to get your FREE
BPH Global Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.